Health organisations urge Novartis to drop patent case

Business line Wednesday, Jan 31, 2007 New Delhi Jan. 30 Health organisations from across the world have came forth in support of the Indian Government in its ongoing legal case against drug manufacturer Novartis and urged the Swiss company to drop its patent case in India. Novartis had filed an application for patenting its cancer [...]

IPAB hears Novartis objection against S Chandrasekaran

Economic times, July3, 2007 The Indian Patent Appellate Board (IPAB) on Monday heard a case that will decide whether S Chandrasekaran, former controller general of patents, will be allowed to hear Novartis appeal for Glivec, or if a new person will be appointed for the case. The Swiss drug major had earlier objected to the [...]

Cancer drug patent case takes new turn

Times of India, June 19, 2007 The much-awaited appeal proceedings in a cancer drug patent case could not begin on Monday as Swiss major Novartis AG, turning the tables on the government, raised a conflict-of-interest objection to the composition of the two-member bench of the Intellectual Property Appellate Board (IPAB). How can an officer who [...]

Novartis may suffer jolt in Glivec case

Financial Express, June 20, 2007 The Intellectual Property Appellate Board (IPAB), which has been formed to give a verdict on various patent cases across the country, may reject Novartis objection on the presence of S Chandrasekharan, the former patent controller, on IPAB. Novartis had objected to Chandrasekharans presence on the board saying he was responsible [...]

Patent act of India faces challenge

In a rather predictable move, Novartis, the swiss multinational company which holds patent for a many medicines used for treating camcer, leukemia, malaria and many others including the the anti retro-viral AIDS medicine has challenged the contentious Section 3(d) introduced via the 2005 Amendments to India’s Patent Act. This unique section which has been specifically [...]